EP0946180A4 - Procede de stimulation de la formation osseuse - Google Patents
Procede de stimulation de la formation osseuseInfo
- Publication number
- EP0946180A4 EP0946180A4 EP97945563A EP97945563A EP0946180A4 EP 0946180 A4 EP0946180 A4 EP 0946180A4 EP 97945563 A EP97945563 A EP 97945563A EP 97945563 A EP97945563 A EP 97945563A EP 0946180 A4 EP0946180 A4 EP 0946180A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- bone formation
- stimulating bone
- stimulating
- formation
- bone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
- C07D223/22—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines
- C07D223/24—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom
- C07D223/26—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom having a double bond between positions 10 and 11
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2776496P | 1996-10-07 | 1996-10-07 | |
US27764P | 1996-10-07 | ||
PCT/US1997/018178 WO1998015278A1 (fr) | 1996-10-07 | 1997-10-07 | Procede de stimulation de la formation osseuse |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0946180A1 EP0946180A1 (fr) | 1999-10-06 |
EP0946180A4 true EP0946180A4 (fr) | 2003-07-23 |
Family
ID=21839659
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP97945563A Withdrawn EP0946180A4 (fr) | 1996-10-07 | 1997-10-07 | Procede de stimulation de la formation osseuse |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP0946180A4 (fr) |
JP (1) | JP2001501951A (fr) |
WO (1) | WO1998015278A1 (fr) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10504825A (ja) * | 1994-08-22 | 1998-05-12 | スミスクライン・ビーチャム・コーポレイション | 二環式化合物 |
US6008213A (en) * | 1995-06-29 | 1999-12-28 | Smithkline Beecham Corporation | Integrin receptor antagonists |
US6576643B2 (en) | 1997-09-19 | 2003-06-10 | Smithkline Beecham Corporation | Vitronectin receptor antagonists |
AR015446A1 (es) * | 1997-09-19 | 2001-05-02 | Smithkline Beecham Corp | Antagonistas de receptores de vitronectina, composicion farmaceutica que los contiene, procedimiento para su preparacion, su uso para la elaboracion de unmedicamento y compuestos intermediarios |
EP1017387A4 (fr) * | 1997-09-24 | 2004-08-18 | Smithkline Beecham Corp | Antagoniste du recepteur de vitronectine |
UA71586C2 (en) | 1998-12-04 | 2004-12-15 | Smithkline Beecham Corp | A vitronectin receptor antagonist |
AUPP794898A0 (en) * | 1998-12-24 | 1999-01-28 | Garvan Institute Of Medical Research | Transgenic animal |
JP2002536370A (ja) * | 1999-02-03 | 2002-10-29 | メルク エンド カムパニー インコーポレーテッド | α−Vインテグリン受容体拮抗薬としてのベンゾアゼピン誘導体 |
EP1198231A1 (fr) | 1999-07-21 | 2002-04-24 | American Home Products Corporation | Antagonistes bicycliques selectifs contre l'integrine(alpha)v (beta)3 |
CN1247258C (zh) | 2001-04-24 | 2006-03-29 | 默克专利有限公司 | 使用抗血管生成剂和TNFα的联合疗法 |
WO2003059251A2 (fr) | 2001-10-22 | 2003-07-24 | The Scripps Research Institute | Composes de ciblage d'anticorps |
MXPA04006709A (es) | 2002-01-11 | 2004-10-04 | Sankyo Co | Derivados de aminoalcohol o derivados de acido fosfonico y composiciones farmaceuticas que los contienen. |
WO2005079788A1 (fr) | 2004-02-24 | 2005-09-01 | Sankyo Company, Limited | Composé d’alcool aminé |
UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
US20090130098A1 (en) | 2006-01-18 | 2009-05-21 | Merck Patent Gmbh | Specific therapy using integrin ligands for treating cancer |
ES2399159T3 (es) | 2007-01-18 | 2013-03-26 | Merck Patent Gmbh | Terapia y medicamento específicos usando ligandos de integrinas para el tratamiento del cáncer |
CA2705916C (fr) | 2007-11-16 | 2016-01-05 | Ube Industries, Ltd. | Compose de benzazepinone |
US8518927B2 (en) | 2009-02-10 | 2013-08-27 | The Scripps Research Institute | Chemically programmed vaccination |
SG176103A1 (en) | 2009-05-25 | 2011-12-29 | Merck Patent Gmbh | Continuous administration of cilengitide in cancer treatments |
EP2878339A1 (fr) | 2013-12-02 | 2015-06-03 | Siena Biotech S.p.A. | Antagonistes SIP3 |
CN103772273A (zh) * | 2014-03-04 | 2014-05-07 | 定陶县友帮化工有限公司 | 2-boc-氨基-3-羟基-5-氯吡啶的合成方法 |
CN103772272A (zh) * | 2014-03-04 | 2014-05-07 | 定陶县友帮化工有限公司 | 2-boc-氨基-3-羟基-5-溴吡啶的合成方法 |
CN103880739A (zh) * | 2014-03-12 | 2014-06-25 | 定陶县友帮化工有限公司 | 一种2-boc-氨基-3-羟基吡啶的合成方法 |
EP3148587B1 (fr) | 2014-05-30 | 2021-02-24 | Pfizer Inc | Dérivés carbonitriles en tant que modulateurs sélectifs du récepteur des androgènes |
WO2023275715A1 (fr) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Métabolites de modulateurs sélectifs du récepteur des androgènes |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5169837A (en) * | 1991-03-28 | 1992-12-08 | Allelix Biopharmaceuticals Inc. | Isolated osteogenic factor |
EP0528587A1 (fr) * | 1991-08-09 | 1993-02-24 | Merck & Co. Inc. | Inhibition de la résorption osseuse causée par osteoclartes utilisant de dérivés phényliques substitués |
US5240961A (en) * | 1992-07-02 | 1993-08-31 | Shug Austin L | Method of treating reduced insulin-like growth factor and bone loss associated with aging |
EP0557663A1 (fr) * | 1992-02-27 | 1993-09-01 | Delmas, Pierre, Dr. | Répartition de fragilité d'os et prédiction de risque de fracture d'ostéoporotique utilisant une détermination quantitative d'ostéocalcine circulante sous-carboxylée |
WO1996000574A1 (fr) * | 1994-06-29 | 1996-01-11 | Smithkline Beecham Corporation | Antagonistes du recepteur de la vibronectine |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3812119A (en) * | 1969-11-21 | 1974-05-21 | Ciba Geigy Corp | Dibenzocycloheptenes |
US5686116A (en) * | 1990-01-12 | 1997-11-11 | New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery | Methods of enhancing repair, healing and augmentation of bone implants |
JP2935541B2 (ja) * | 1990-06-28 | 1999-08-16 | サントリー株式会社 | 縮合複素環化合物 |
JPH0792165A (ja) * | 1993-09-21 | 1995-04-07 | Hoechst Japan Ltd | 骨粗鬆症診断剤 |
CA2193966A1 (fr) * | 1994-06-29 | 1996-01-11 | Fadia El-Fehail Ali | Antagonistes du recepteur de la vitronectine |
JPH10504825A (ja) * | 1994-08-22 | 1998-05-12 | スミスクライン・ビーチャム・コーポレイション | 二環式化合物 |
WO1996026190A1 (fr) * | 1995-02-22 | 1996-08-29 | Smithkline Beecham Corporation | Antagonistes des recepteurs a l'integrine |
-
1997
- 1997-10-07 WO PCT/US1997/018178 patent/WO1998015278A1/fr not_active Application Discontinuation
- 1997-10-07 JP JP10517727A patent/JP2001501951A/ja active Pending
- 1997-10-07 EP EP97945563A patent/EP0946180A4/fr not_active Withdrawn
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5169837A (en) * | 1991-03-28 | 1992-12-08 | Allelix Biopharmaceuticals Inc. | Isolated osteogenic factor |
EP0528587A1 (fr) * | 1991-08-09 | 1993-02-24 | Merck & Co. Inc. | Inhibition de la résorption osseuse causée par osteoclartes utilisant de dérivés phényliques substitués |
EP0557663A1 (fr) * | 1992-02-27 | 1993-09-01 | Delmas, Pierre, Dr. | Répartition de fragilité d'os et prédiction de risque de fracture d'ostéoporotique utilisant une détermination quantitative d'ostéocalcine circulante sous-carboxylée |
US5240961A (en) * | 1992-07-02 | 1993-08-31 | Shug Austin L | Method of treating reduced insulin-like growth factor and bone loss associated with aging |
WO1996000574A1 (fr) * | 1994-06-29 | 1996-01-11 | Smithkline Beecham Corporation | Antagonistes du recepteur de la vibronectine |
Non-Patent Citations (1)
Title |
---|
See also references of WO9815278A1 * |
Also Published As
Publication number | Publication date |
---|---|
JP2001501951A (ja) | 2001-02-13 |
EP0946180A1 (fr) | 1999-10-06 |
WO1998015278A1 (fr) | 1998-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0946180A4 (fr) | Procede de stimulation de la formation osseuse | |
IL126203A0 (en) | Method for treating pain | |
EP0906104A4 (fr) | Procede de traitement de la douleur | |
HUP9700851A3 (en) | Method for producing l-lysin | |
AU9035498A (en) | Method for treating pain | |
GB2319796B (en) | Formation treatment method using deformable particles | |
IL118196A0 (en) | Methods for inhibiting bone loss | |
ZA977564B (en) | Method of treatment | |
IL127620A0 (en) | Method for producing therapeutic DNA | |
IL129761A0 (en) | Method for preparing cyclopropylamines | |
IL126064A0 (en) | Method for treating pain | |
GB9605828D0 (en) | Treatment method | |
HUP0000554A3 (en) | Method for producing n-substituted 3-hydroxipyrazoles | |
HUP9802589A3 (en) | Bone stimulating factor | |
IL124786A0 (en) | Method for treating pain | |
GB2359316B (en) | Formation treatment method using deformable particles | |
AU2810497A (en) | Methods for inducing bone formation | |
AU9034798A (en) | Method for treating pain | |
GB9714841D0 (en) | Treatment method | |
ZA973988B (en) | Method of treatment | |
GB9618341D0 (en) | Method of treatment | |
ZA968062B (en) | Bone stimulating factor | |
IL130092A0 (en) | Method for producing 2-chloro-5-aminomethylthiazole from 2-chloro-5-methylthiazole via 2-chloro-5-chloromethylthiazole | |
GB9604739D0 (en) | Surgical method | |
GB9824573D0 (en) | Methods for stimulating bone formation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19990409 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): BE CH DE ES FR GB IT LI NL |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20030605 |
|
17Q | First examination report despatched |
Effective date: 20030901 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20040113 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1023061 Country of ref document: HK |